Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Pharmaceutical
GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Pharmaceutical
Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Miami, USA-based OPKO Health (NYSE: OPK) has entered into a definitive agreement to acquire a 45% stake in an unnamed private Israeli company that produces a third-generation hepatitis B vaccine - Sci-B-Vac - in its state of the art biologics manufacturing facility in Rehovot. Financial terms of the transaction were not disclosed. 6 June 2012
Pharmaceutical
Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) said yesterday that it has now completed its previously-announced acquisition of privately-held US company URL Pharma, for an upfront payment of $800 million (The Pharma Letter April 12). 6 June 2012
Pharmaceutical
UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile takeover offer for Human Genome Sciences (NSQ: HGSI) unless the U.S. biotechnology company dropped a shareholder rights plan or "poison pill" imposed to block the deal, Reuters and other news sources have reported. 24 May 2012
Pharmaceutical
USA-based Agilent Technologies (NYSE: A) and EQT, a Swedish private equity group, have entered into an accord to acquire Denmark-based cancer diagnostic company Dako. The $2.2 billion all cash acquisition (on a debt-free basis) is the largest in Agilent's history. 21 May 2012
Pharmaceutical
In a second acquisition move within a matter of months, USA-based specialty drugmaker Cornerstone Therapeutics has made a takeover bid for EKR Therapeutics, a privately-held specialty pharmaceutical company focused on the acute-care hospital setting. 16 May 2012
Pharmaceutical
Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has agreed to acquire certain assets from University Medical Pharmaceuticals Corp, a specialty pharmaceutical company focused on skincare products, for approximately $64 million plus potential milestones based upon attainment of future revenue targets. University Medical's main brand is AcneFree, a leading retail over-the-counter (OTC) acne treatment. 4 May 2012
Pharmaceutical
USA-based Hologic (Nasdaq: HOLX) said it has reached an agreement to acquire Gen-Probe (Nasdaq: ASDAQ) for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion. The all-cash transaction, approved by both companies' boards of directors, is expected to be funded through available cash and additional financing of term loans and high yield securities. The transaction is expected to be completed in the second half of calendar 2012. 3 May 2012
Pharmaceutical
USA-based Pall Corp (NYSE: PLL) has entered into an agreement to sell certain assets of its blood collection, filtration and processing product lines, as well as equipment for transfusion medicine, to Haemonetics Corp (NYSE: HAE) for around $550 million. 30 April 2012
Pharmaceutical
US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) said last week that it has signed a definitive accord to acquire privately-held, UK-headquartered EUSA Pharma for $650 million in cash and a potential $50 million milestone. 29 April 2012
Pharmaceutical
Swiss food giant Nestle has won the battle to acquire the Nutrition business of global drugs behemoth Pfizer (NYSE: PFE), beating potential buyers France's Danone and USA-based Mead Johnson Nutrition, with a $11.85 billion in cash offer. Pfizer had previously announced its intention to sell its Nutrition business, which recorded revenues of around $2.1 billion in 2011, an increase of 15% versus 2010. 24 April 2012
Pharmaceutical
The European Commission last week cleared under the EU Merger Regulation the proposed $21.3 billion acquisition of Synthes by Johnson & Johnson (NYSE: JNJ), both companies active in the area of orthopedic medical devices, announced a year ago (The Pharma Letter April 27, 2011). 22 April 2012
Pharmaceutical
Indian drugmaker Piramal Healthcare (BSE: 500302) says it has signed an agreement to acquire worldwide rights to the molecular imaging R&D portfolio of German group Bayer (BAY: DE) through its newly created subsidiary - Piramal Imaging SA. 16 April 2012
Pharmaceutical
If there is an axiom to describe Swiss drug major Roche (ROG: SIX), it is that what Roche wants, it gets, says Jerry Isaacson, head of the GlobalData health care industry dynamics team, commenting on the ongoing sage of the hostile takeover activities regarding USA-based Illumina (The Pharma Letters passim). 16 April 2012
Pharmaceutical
Ireland-headquartered biopharma firm Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire substantially all the assets of Pervasis Therapeutics, a Florida, USA-base clinical stage drug developer. 13 April 2012
Pharmaceutical
In a fourth takeover deal so far this year, Canadian drugmaker Valeant Pharmaceuticals International. (TSX: VRX) says that it has acquired Pedinol Pharmacal, a podiatry-focused, privately-owned specialty pharmaceutical company based in the USA. 13 April 2012
Pharmaceutical
Japanese drug major Takeda Pharmaceutical (TYO: 4502) said yesterday that it has reached agreement to acquire privately-held US firm URL Pharma for an upfront consideration of $800 million with possible additional future performance-based payments. 12 April 2012
Pharmaceutical
Italian drug developer Newron Pharmaceuticals (SIX: NWRN) says that it has signed a strategic collaboration and licence option with privately-held Zambon, also Based in Italy, for its lead compound safinamide, rights to which were returned to Newron last year by Merck Serono and effective April 17 this year (The Pharma Letter October 24, 2011). 9 April 2012
Pharmaceutical
Belgium-based Ion Beam Applications (IBA.) and SK Capital Partners, a US private investment firm, have finalized their agreement to create IBA Molecular, a jointly-owned company derived from IBA's worldwide radiopharmaceutical division. The transaction is valued at around 180 million euros ($234 million), with SK Capital owning 60% of the recapitalized entity and IBA retaining a 40% stake. Pending regulatory approval, the transaction is expected to close by the second quarter. 9 April 2012
Pharmaceutical
Swiss drug major Roche (ROG: SIX), admitting disappointment that the board of Illumina (Nasdaq: ILMN) has rejected its increased offer, is nevertheless pushing ahead with its hostile tender offer for the USA-based provider of integrated systems for DNA sequencing (The Pharma Letters January 25 and March 29). 4 April 2012
Pharmaceutical
UK pharma giant GlaxoSmithKline (LSE: GSK) has increased its equity stake in USA-based Theravance (Nasdaq: THRX), its respiratory products development partner, acquiring 10 million newly-issued shares in the latter at a price of $21.2887 per share, for a total investment of around $212.9 million. 3 April 2012
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze